C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.…
Is C4 Therapeutics (CCCC) Outperforming Other Medical Stocks This Year?
C4 Therapeutics (NASDAQ: CCCC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 104 employees.
The shares were at 2.480 USD on 20 November 2026, up 6.0% over 52 weeks. Its 52-week range is 1.690 USD to 5.170 USD: the price is 52.0% below the high and 46.7% above the low.
Its market capitalisation is 325.67M USD.
C4 Therapeutics reports return on equity of -40.9%, an operating margin of -315.9% and revenue down 24.6% year over year.
It holds more cash than debt, a net cash position of 150.15M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 25 February 2027.